Mpox Vaccine Shows Immune Response In Adolescents Similar To That Of Adults With No Safety Signals Six Months After Last Dose, Study Finds

Managed Healthcare Executive (10/16, Myshko) reports, “Modified vaccinia Ankara-Bavarian Nordic (MVA-BN), a vaccine to prevent mpox infection, showed immune response in adolescents similar to that of adults with no safety signals six months after the last dose, according to interim results from a U.S. phase 2 trial.” Researchers found that “dizziness was more common in adolescents (3% versus none in adults) but similar to rates reported after other adolescent vaccines.” The findings were presented at IDWeek.